Azitra, Inc. (NYSE: AZTR)

Azitra, Inc., a clinical-stage biopharmaceutical company, is focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products (Azitra, Inc.). The company's main business activities involve the development of genetically engineered strains of Staphylococcus epidermidis, which is a strong therapeutic candidate species due to its beneficial effects as a commensal, naturally occurring microbe on the skin (Azitra, Inc.). Azitra's primary products are ATR-12, ATR-04, and ATR-01, which are genetically modified strains of S. epidermidis that have been engineered to express and secrete specific proteins or peptides (Azitra, Inc.).

Azitra's proprietary platform includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. This platform allows the company to develop living organisms or engineered proteins with significant therapeutic effect, and has been used to create distinct bacterial species that are capable of being engineered for various skin diseases (Azitra, Inc.). Azitra's competitive advantages include its proprietary platform and its ability to engineer bacterial strains to express specific proteins or peptides, as well as its partnership with the Fred Hutchinson Cancer Center, which provides access to proprietary technology for the production of proteins in previously intractable bacterial species (Azitra, Inc.).

Azitra's customers are primarily researchers and clinicians in the field of dermatology, who are interested in using the company's products to develop new treatments for skin diseases. The company has also partnered with Bayer Consumer Care AG, the consumer products division of Bayer AG, to develop and commercialize certain product candidates (Azitra, Inc.). Azitra's products have the potential to treat a range of skin diseases, including Netherton syndrome, EGFRi-associated rash, and ichthyosis vulgaris (Azitra, Inc.).

ATR-12 is a topical ointment that contains an S. epidermidis strain, SE351, that has been genetically modified to express LEKTI, a protein that is deficient in Netherton syndrome patients. The company believes that ATR-12 has the potential to be the first therapy to effectively treat Netherton syndrome, a disease for which there is currently no known cure (Azitra, Inc.). ATR-04 is a topical application intended to address the papulopustular rash experienced by cancer patients undergoing EGFRi targeted therapy. The company believes that ATR-04 has the potential to reduce the need for antibiotics in these patients and lead to fewer adverse events due to EGFRi and antibiotic use (Azitra, Inc.). ATR-01 is a topical application intended to treat ichthyosis vulgaris, a chronic scaly skin disease with an estimated incidence and prevalence of 1 in 250 (Azitra, Inc.).

Azitra's position within the industry is unique due to its proprietary platform and expertise in microbial engineering, which make it a pioneer in genetically engineering bacteria for therapeutic use in dermatology. The company's competitors include other biopharmaceutical companies that are developing therapies for skin diseases, such as Pfizer and Johnson & Johnson (Azitra, Inc.).